Table 2.
Variables, N (%) | LDLRAD4 expression | p-value | |
---|---|---|---|
Low (N = 221) | High (N = 55) | ||
Gender | 0.555 | ||
Male | 131 (59.3) | 35 (63.6) | |
Female | 90 (40.7) | 20 (36.4) | |
Age | 0.027 | ||
<60 | 129 (58.4) | 41 (74.5) | |
≥60 | 92 (41.6) | 14 (25.5) | |
TNM stage | 0.139 | ||
I | 18 (8.1) | 3 (5.4) | |
II | 66 (29.9) | 15 (27.3) | |
III | 99 (44.8) | 33 (60.0) | |
IV | 38 (17.2) | 4 (7.3) | |
T stage | 0.461 | ||
T2 | 37 (16.7) | 6 (10.9) | |
T3 | 41 (18.6) | 13 (23.6) | |
T4 | 143 (64.7) | 36 (65.5) | |
N stage | 0.881 | ||
N0 | 98 (44.3) | 22 (40.0) | |
N1 | 65 (29.5) | 18 (32.7) | |
N2 | 58 (26.2) | 15 (27.3) | |
M stage | 0.067 | ||
M0 | 183 (82.8) | 51 (92.7) | |
M1 | 38 (17.2) | 4 (7.3) | |
Tumor location | 0.489 | ||
Colon | 101 (45.7) | 28 (50.9) | |
Rectum | 120 (54.3) | 27 (49.1) | |
Grade | 0.728 | ||
Well/moderate | 177 (80.1) | 43 (78.2) | |
Poor | 44 (19.9) | 12 (21.8) | |
Histological type | 0.511 | ||
Adenocarcinoma | 208 (94.1) | 53 (96.4) | |
Mucinous | 13 (5.9) | 2 (3.6) | |
LNH | 0.171 | ||
<12 | 69 (31.2) | 12 (21.8) | |
≥12 | 152 (68.8) | 43 (78.2) | |
Perineural invasion | 0.934 | ||
Negative | 185 (84.1) | 46 (83.6) | |
Positive | 35 (15.9) | 9 (16.4) | |
Vascular invasion | 0.954 | ||
Negative | 148 (67.0) | 36 (65.5) | |
Positive | 70 (31.7) | 18 (32.7) | |
Unknown | 3 (1.3) | 1 (1.8) | |
Pre-treatment CEA | 0.623 | ||
Negative | 133 (60.2) | 37 (67.3) | |
Positive | 79 (35.7) | 16 (29.1) | |
Unknown | 9 (4.1) | 2 (3.6) | |
Adjuvant chemotherapy | 0.026 | ||
No | 41 (18.5) | 8 (14.6) | |
Yes | 144 (65.2) | 45 (81.8) | |
Unknown | 36 (16.3) | 2 (3.6) | |
MSI status/MMR status | 0.004 | ||
MSS/MMR-proficient | 150 (67.9) | 26 (47.3) | |
MSI/MMR-deficient | 71 (32.1) | 29 (52.7) |
LNH number of lymph nodes harvested, CEA carcinoembryonic antigen, MSI microsatellite instability, MSS microsatellite stability, MMR mismatch repair.